Lates News

According to AI news, Huayuan Securities released a research report on April 28th, giving China National Pharmaceutical Group Corp. (600511.SH) a buy rating. The rating reasons mainly include: 1) The steady growth of the parent company's revenue and profit, with the gross profit margin and expense ratio basically maintained stable; 2) The gross profit margin of the consolidated financial statements has slightly declined, and the cost control is good. (Daily Economic News)